Scholarlink

Background <p>Prevention of progression of chronic kidney disease (CKD) is one of the main tasks in nephrology.</p> Question <p>Available scientific evidence for drug treatment to halt CKD progression is discussed.</p> Material and methods <p>Structured literature search in PubMed.</p> Results <p>There is strong evidence supporting the use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin II type 1 (AT1) receptor blockers in patients with confirmed CKD. Sodium-glucose transporter 2 (SGLT-2) inhibitors are particularly beneficial in proteinuric patients. The newer glucagon-like peptide 1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists and finerenone have also been shown to be effective in patients with type&#xa0;2 diabetes and diabetic kidney damage.</p> Conclusion <p>The pharmacotherapeutic options for slowing CKD progression have expanded considerably in recent years. This is particularly true for patients with type&#xa0;2 diabetes mellitus. It remains to be seen to what extent CKD patients with other underlying kidney diseases will benefit from GLP-1/GIP receptor agonists and finerenone. The role of combination therapy (fantastic four) also needs to be evaluated. Furthermore, new biomarkers are needed that can predict CKD progression better and thus enable individualized treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prävention und Progressionshemmung der chronischen Nierenerkrankung

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • David Schmit,
  • J. Lämmerzahl,
  • S. Neuhaus,
  • A. Sellier

摘要

Background

Prevention of progression of chronic kidney disease (CKD) is one of the main tasks in nephrology.

Question

Available scientific evidence for drug treatment to halt CKD progression is discussed.

Material and methods

Structured literature search in PubMed.

Results

There is strong evidence supporting the use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin II type 1 (AT1) receptor blockers in patients with confirmed CKD. Sodium-glucose transporter 2 (SGLT-2) inhibitors are particularly beneficial in proteinuric patients. The newer glucagon-like peptide 1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists and finerenone have also been shown to be effective in patients with type 2 diabetes and diabetic kidney damage.

Conclusion

The pharmacotherapeutic options for slowing CKD progression have expanded considerably in recent years. This is particularly true for patients with type 2 diabetes mellitus. It remains to be seen to what extent CKD patients with other underlying kidney diseases will benefit from GLP-1/GIP receptor agonists and finerenone. The role of combination therapy (fantastic four) also needs to be evaluated. Furthermore, new biomarkers are needed that can predict CKD progression better and thus enable individualized treatment.